Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 6:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Insulin Glargine (HOE901 - U300) Clear all

Conditions: Type 2 Diabetes
Interventions: Glargine U300, Glargine U100, Glulisine Insulin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 811 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 110
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more

Conditions: Type 2 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 95
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 78 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 74
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 64
States / cities: Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more

Conditions: Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
Interventions: Discharge Order Set (DOS), Enhanced Standard Care (ESC); Other
Lead sponsor: Ohio State University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 99
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 80 more

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Temecula, California • Minneapolis, Minnesota • Portland, Oregon

Conditions: Type 2 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 117
States / cities: Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes Mellitus, Renal Impairment
Interventions: Insulin glargine 300 U/mL, Insulin degludec 100 U/mL; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 32
States / cities: Yuma, Arizona • Buena Park, California • Canyon Country, California + 26 more

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 82
States / cities: Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more

Search by objective public record fields.

Glargine U300 Hospital Trial

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus